MX2021004412A - Cocristales que comprenden levotiroxina y un acido dicarboxilico. - Google Patents

Cocristales que comprenden levotiroxina y un acido dicarboxilico.

Info

Publication number
MX2021004412A
MX2021004412A MX2021004412A MX2021004412A MX2021004412A MX 2021004412 A MX2021004412 A MX 2021004412A MX 2021004412 A MX2021004412 A MX 2021004412A MX 2021004412 A MX2021004412 A MX 2021004412A MX 2021004412 A MX2021004412 A MX 2021004412A
Authority
MX
Mexico
Prior art keywords
levothyroxine
crystals
dicarboxylic acid
present
acid
Prior art date
Application number
MX2021004412A
Other languages
English (en)
Inventor
Ulrich Griesser
Marijan Stefinovic
Dennis Dimo Enkelmann
Thomas Gelbrich
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of MX2021004412A publication Critical patent/MX2021004412A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se relaciona a cocristales que comprenden levotiroxina y un ácido dicarboxílico, preferentemente ácido L-tartárico o ácido oxálico, y procesos para la preparación de los mismos. Adicionalmente, la invención se relaciona a una composición farmacéutica que comprende un cocristal de la presente invención, preferentemente el cocristal que comprende levotiroxina y ácido L-tartárico o ácido oxálico, y por lo menos un excipiente aceptable farmacéuticamente. La composición farmacéutica de la presente invención puede ser usada como un medicamento, en particular para el tratamiento de hipotiroidismo.
MX2021004412A 2018-10-17 2019-10-16 Cocristales que comprenden levotiroxina y un acido dicarboxilico. MX2021004412A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18200869 2018-10-17
EP19201020 2019-10-02
PCT/EP2019/078084 WO2020079079A1 (en) 2018-10-17 2019-10-16 Co-crystals comprising levothyroxine and a dicarboxylic acid

Publications (1)

Publication Number Publication Date
MX2021004412A true MX2021004412A (es) 2021-07-06

Family

ID=68240756

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004412A MX2021004412A (es) 2018-10-17 2019-10-16 Cocristales que comprenden levotiroxina y un acido dicarboxilico.

Country Status (9)

Country Link
US (1) US20210395186A1 (es)
EP (1) EP3866923A1 (es)
JP (1) JP2022505325A (es)
CN (1) CN112930212A (es)
AU (1) AU2019360377A1 (es)
BR (1) BR112021007377A2 (es)
CA (1) CA3113770A1 (es)
MX (1) MX2021004412A (es)
WO (1) WO2020079079A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2422938A (en) * 1943-07-31 1947-06-24 American Dairies Inc Method of extracting l-thyroxine from thyroprotein
GB9401879D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US7858663B1 (en) * 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
MX2010004222A (es) * 2007-10-19 2010-09-14 Purdue Research Foundation Formulaciones solidas de compuestos cristalinos.
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CA2771564C (en) * 2012-01-06 2018-08-28 Ordway Research Institute, Inc. Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
US20180064669A1 (en) * 2016-05-03 2018-03-08 Spectrix Therapeutics, LLC Compositions and methods of providing thyroid hormone or analogs thereof
CN108250219B (zh) * 2017-12-25 2019-01-29 佳木斯大学附属第一医院 一种治疗甲状腺炎的药物及其制备方法

Also Published As

Publication number Publication date
CA3113770A1 (en) 2020-04-23
WO2020079079A1 (en) 2020-04-23
AU2019360377A1 (en) 2021-04-29
CN112930212A (zh) 2021-06-08
BR112021007377A2 (pt) 2021-07-20
JP2022505325A (ja) 2022-01-14
EP3866923A1 (en) 2021-08-25
US20210395186A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
MX2019012884A (es) Terapia de combinacion.
JP2015517488A5 (es)
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
WO2019073331A3 (en) Pharmaceutical compositions of apremilast
CO2019006652A2 (es) Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.
PH12018502089A1 (en) Pharmaceutical composition of dapagliflozin
MX2020008360A (es) Forma cristalina de bictegravir sodico.
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
MX2021004412A (es) Cocristales que comprenden levotiroxina y un acido dicarboxilico.
MD20180049A2 (ro) Compoziţie farmaceutică
MX2021015441A (es) Formas cristalinas de cabotegravir de sodio.
MX2010011193A (es) Composicion farmaceutica liquida para el tratamiento y prevencion del dolor.
EA202091561A1 (ru) Фармацевтическая композиция, содержащая фармацевтически приемлемую кислотно-аддитивную соль леналидомида
BR112018008835A8 (pt) composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla
EA201100682A1 (ru) Стабильная фармацевтическая композиция, содержащая прегабалин, капсула, ее содержащая, способ получения и применение
EA201691763A1 (ru) Стабильная быстрорастворимая лекарственная форма, содержащая амоксициллин и клавулановую кислоту
MX2017012999A (es) Acido pirrolidona carboxilico (pca) para uso oftalmico.
MX2021014673A (es) Combinacion de dosis fija de liberacion inmediata de memantina y donepezil.
MA35698B1 (fr) Nouvelle composition du 3,4-diaminopyridin pour le traitement de la fatigabilité musculaire associée à des troubles neurovégétatifs.
EA201400974A1 (ru) Композиция для лечения рассеянного склероза (варианты)
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой
ZA202204907B (en) Orally disintegrating pharmaceutical compositions of apixaban
EA202091903A1 (ru) Кристаллическая форма битегравир-натрия